![](/media/vdqhqzem/salmon.png)
Uppsala Reports editor
@UMCGlobalSafety
Jean Marie Vianney Habarugira and Albert Figueras are all for using pharmacovigilance databases for AMR surveillance. Hear them out on the latest episode of Drug Safety Matters.
Managing antimicrobial resistance (AMR) will require innovative solutions from many different disciplines. Could pharmacovigilance be one of them?
In the latest episode of Drug Safety Matters, Jean Marie Vianney Habarugira and Albert Figueras, who have been investigating how drug safety tools could help track AMR, tell podcast host Federica Santoro why they think it’s time the two communities joined forces for good.
Subscribe by visiting the Drug Safety Matters website or listen in right here:
When it comes to pharmacovigilance in older patients, age alone is insufficient as a measure of adverse reaction risk. Here is what we should consider instead.
Research / 13 May 2024
The traditional “drug-event combination” approach is too simplistic for complex side effects such as behavioural changes. We must adjust our methodology to address this intricacy.
Research / 29 May 2024
Adverse effects to medicines are not just physical in nature, but can manifest as behavioural side-effects too. How do we diagnose and treat these complex ADRs?
Research / 02 May 2024